Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261563 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL18512865 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805336 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL659091 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL15810727 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL28738894 | 0.92 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL23547665 | 0.91 | LMNA (0.37) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21999057 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL23547707 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21999226 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649153-A1 | MODIFIED MULTI-SEGMENTED ANTISENSE OLIGONUCLEOTIDES FOR USE | Ausperbio Therapeutics Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4632075-A2 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-10-15 | — | — | EP | claimed |
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| EP-4029522-B1 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| US-20250215430-A1 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | AUSPERBIO THERAPEUTICS INC. | 2025-07-03 | — | — | US | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250161488-A1 | THERAPEUTIC mRNA | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-22 | — | — | US | claimed |
| EP-4486909-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| EP-0813539-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050059815-A1 | Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | COOK PHILLIP DAN (US) | 2005-03-17 | — | — | US | claimed |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ISIS PHARMACEUTICALS, INC. | 2003-03-13 | — | — | US | claimed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | claimed |
| US-5767270-A | PROTECTING EXOCYCLIC AMINO GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059815-A1 | Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | NUDT1, DPYD, UMPS | LMNA 3765/4885MTOR 4149/4885ALDH1A1 842/4885 |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ATIC, TYMS, RRM2 | LMNA 3797/4885MTOR 4007/4885ALDH1A1 940/4885 |
| US-20250215430-A1 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | HAVCR2, WNT1, SRRT | LMNA 780/4885MTOR 4042/4885ALDH1A1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.